The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
You are here Home Guidance and resources Sponsors BeiGene AUS Pty Ltd Regulatory activities for this sponsor. Listen Print Share Loading... Type Designation or determination (3) (-) Designation or determination (3) Prescription medicine registration (6) Prescription medicine registration (6) Australian Public Assessment Report (AusPAR) (4) Australian Public Assessment Report (AusPAR) (4) Prescription medicine decision summary (3) Prescription medicine decision summary (3) ARTG (2) ARTG (2) Prescription medicine evaluation (2) Prescription medicine evaluation (2) Cancellation by sponsor (1) Cancellation by sponsor (1) Show more Date 2023 (1) 2023 (1) 2021 (1) 2021 (1) 2020 (1) 2020 (1) Search Filters applied:Designation or determinationClear all Sponsor content3 result(s) found, displaying 1 to 3 Notice for tislelizumab (Beigene Aus Pty Ltd) 23 October 2023 Designation or determination Orphan drug Notice for zanubrutinib (BeiGene AUS Pty Ltd) 20 September 2021 Designation or determination Provisional approval Notice for zanubrutinib (BeiGene Aus Pty Ltd) 17 June 2020 Designation or determination Provisional approval
Notice for tislelizumab (Beigene Aus Pty Ltd) 23 October 2023 Designation or determination Orphan drug
Notice for zanubrutinib (BeiGene AUS Pty Ltd) 20 September 2021 Designation or determination Provisional approval
Notice for zanubrutinib (BeiGene Aus Pty Ltd) 17 June 2020 Designation or determination Provisional approval